Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer

被引:0
作者
Tengyue Zeng
Libing Zhu
Min Liao
Wenli Zhuo
Shunliang Yang
Weizhen Wu
Dong Wang
机构
[1] Fujian Medical University,Department of Urology, Fuzhou General Hospital
[2] Lushan Sanatorium of the PLA,Department of Urology
来源
Medical Oncology | 2017年 / 34卷
关键词
Prostate cancer; PYCR1; Cell proliferation; Cell cycle; Apoptosis; AR signaling;
D O I
暂无
中图分类号
学科分类号
摘要
Pyrroline-5-carboxylate reductase 1 (PYCR1) is an enzyme involved in cell metabolism, which has been shown to be up-regulated in cancers. However, the functions of PYCR1 in prostate cancers (PCa) are still largely unknown. In the present study, we found that PYCR1 was highly expressed in prostate cancer tissues and then knocked down PYCR1 in PCa cell lines (DU145, PC-3 and LNCap) via lentivirus-mediated gene delivery and analyzed its biological function. Both qRT-PCR and western blotting indicated that PYCR1 was suppressed efficiently after sh-PYCR1 infection. Further analysis indicated knockdown of PYCR1 significantly inhibited PCa cell growth and colony formation ability. The inhibition effects on growth were likely due to G2/M-phase arrest and enhanced cell apoptosis, as determined by flow cytometer analysis. At last, we verified the expression levels of cell cycle regulatory proteins, including CDK1, CDK2, CDK4 and Cyclin B1 were all downregulated and cell apoptotic-related proteins, including cleaved caspase 3 and cleaved PARP were increased in PCa cells after PYCR1 knockdown. Furthermore, PYCR1 has been shown not to be directly regulated by androgen receptor (AR) levels. These results show the functions of PYCR1 in PCa tumorigenesis for the first time and suggest that PYCR1 might be a good potential therapy approach for treating PCa.
引用
收藏
相关论文
共 98 条
[1]  
Ferlay J(2013)Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 1374-1403
[2]  
Steliarova-Foucher E(2013)Epidemiology of prostate cancer in the Asia-Pacific region Prostate Int 1 47-58
[3]  
Lortet-Tieulent J(2004)Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer Endocr Relat Cancer 11 459-476
[4]  
Rosso S(2014)Current management of advanced and castration resistant prostate cancer Can J Urol 21 1-6
[5]  
Coebergh JW(2014)Human pyrroline-5-carboxylate reductase (PYCR1) acts on Delta(1)-piperideine-6-carboxylate generating L-pipecolic acid J Inherit Metab Dis 37 327-332
[6]  
Comber H(2009)Mutation in pyrroline-5-carboxylate reductase 1 gene in families with cutis laxa type 2 Am J Hum Genet 85 120-129
[7]  
Baade PD(2009)Mutations in PYCR1 cause cutis laxa with progeroid features Nat Genet 41 1016-1021
[8]  
Youlden DR(2011)Defect in proline synthesis: pyrroline-5-carboxylate reductase 1 deficiency leads to a complex clinical phenotype with collagen and elastin abnormalities J Inherit Metab Dis 34 731-739
[9]  
Cramb SM(2011)A novel mutation in PYCR1 causes an autosomal recessive cutis laxa with premature aging features in a family Am J Med Genet Part A 155A 1285-1289
[10]  
Dunn J(2013)Genotype-phenotype spectrum of PYCR1-related autosomal recessive cutis laxa Mol Genet Metab 110 352-361